Copyright
©The Author(s) 2024.
World J Clin Oncol. Jul 24, 2024; 15(7): 859-866
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.859
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.859
Feature | Observation group | Control group |
Age in yr | ||
Median | 57 | 55 |
Range | 18-70 | 49-80 |
Sex | ||
Male | 20 | 16 |
Female | 14 | 14 |
Performance status | ||
0 | 29 | 28 |
1 | 5 | 2 |
Stage | ||
Stage A | 21 | 17 |
Stage B | 13 | 13 |
- Citation: Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma. World J Clin Oncol 2024; 15(7): 859-866
- URL: https://www.wjgnet.com/2218-4333/full/v15/i7/859.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i7.859